CPTX-2309

N/A

Report date: 2026/05/13 09:07:30

Base Information

Drug NameCPTX-2309

Drug Alias NameCPTX-2309CPTX2309ABBV-619

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate > Ab-tLNPCell and gene therapy > Gene therapy > LNPCell and gene therapy > Gene therapy > mRNA +[4]

Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustralia

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesCapstan Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesCapstan Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsAutoimmune DiseasesLupus Erythematosus, SystemicArthritis, Rheumatoid

Inactive IndicationsN/A

Other Information

ATC CodeN/A